A multi-center, double-blind, randomized, placebo-controlled, parallel-group, multiple-ascending-dose study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of R1511 in type 2 diabetic (T2D) patients.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2016
At a glance
- Drugs R 1511 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2008 Status changed from recruiting to completed, according to clinicaltrials.gov.
- 16 Jul 2008 The expected completion date for this trial is now 1 Jan 2009, according to clinicaltrials.gov record.